Biostax Company Description
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products.
Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS).
Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.
The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023.
Biostax Corp. is headquartered in Orlando, Florida.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Noreen Griffin |
Contact Details
Address: 1317 Edgewater Dr. Orlando, Florida 32804 United States | |
| Phone | 888 391 9355 |
| Website | biostaxcorp.com |
Stock Details
| Ticker Symbol | BTAX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US45252A1079 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Noreen M. Griffin | Founder, Executive Vice President of Business Development and Chief Executive Officer |
| Kelly O'Brien Wilson | President |
| Glen A. Farmer M.B.A. | Chief Financial Officer |
| Robert Wilson | Vice President of Strategy and Director |
| Cynthia Douglas | Company Secretary |
| Dr. Joseph M. Fortunak | Vice President of Global Research and Development and Chemical Development |